Literature DB >> 36053397

Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.

Victoria C Ziesenitz1,2, Tatjana Welzel3,4, Madelé van Dyk5, Patrick Saur6, Matthias Gorenflo6, Johannes N van den Anker3,7,8.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in infants, children, and adolescents worldwide; however, despite sufficient evidence of the beneficial effects of NSAIDs in children and adolescents, there is a lack of comprehensive data in infants. The present review summarizes the current knowledge on the safety and efficacy of various NSAIDs used in infants for which data are available, and includes ibuprofen, dexibuprofen, ketoprofen, flurbiprofen, naproxen, diclofenac, ketorolac, indomethacin, niflumic acid, meloxicam, celecoxib, parecoxib, rofecoxib, acetylsalicylic acid, and nimesulide. The efficacy of NSAIDs has been documented for a variety of conditions, such as fever and pain. NSAIDs are also the main pillars of anti-inflammatory treatment, such as in pediatric inflammatory rheumatic diseases. Limited data are available on the safety of most NSAIDs in infants. Adverse drug reactions may be renal, gastrointestinal, hematological, or immunologic. Since NSAIDs are among the most frequently used drugs in the pediatric population, safety and efficacy studies can be performed as part of normal clinical routine, even in young infants. Available data sources, such as (electronic) medical records, should be used for safety and efficacy analyses. On a larger scale, existing data sources, e.g. adverse drug reaction programs/networks, spontaneous national reporting systems, and electronic medical records should be assessed with child-specific methods in order to detect safety signals pertinent to certain pediatric age groups or disease entities. To improve the safety of NSAIDs in infants, treatment needs to be initiated with the lowest age-appropriate or weight-based dose. Duration of treatment and amount of drug used should be regularly evaluated and maximum dose limits and other recommendations by the manufacturer or expert committees should be followed. Treatment for non-chronic conditions such as fever and acute (postoperative) pain should be kept as short as possible. Patients with chronic conditions should be regularly monitored for possible adverse effects of NSAIDs.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36053397     DOI: 10.1007/s40272-022-00514-1

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.930


  302 in total

Review 1.  Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.

Authors:  C Litalien; E Jacqz-Aigrain
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

2.  A survey of medicine use in children and adolescents in Austria.

Authors:  Elisabeth Rauch; Florian B Lagler; Harald Herkner; Walter Gall; Robert Sauermann; Silvia Hetz; Christoph Male
Journal:  Eur J Pediatr       Date:  2018-07-05       Impact factor: 3.183

Review 3.  Pain control: non-steroidal anti-inflammatory agents.

Authors:  Evelyne Jacqz-Aigrain; Brian J Anderson
Journal:  Semin Fetal Neonatal Med       Date:  2006-05-05       Impact factor: 3.926

Review 4.  Efficacy and Safety of Ibuprofen in Infants Aged Between 3 and 6 Months.

Authors:  Victoria C Ziesenitz; Andreas Zutter; Thomas O Erb; Johannes N van den Anker
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

5.  Use of nonsteroidal anti-inflammatory drugs in infants. A survey of members of the Association of Paediatric Anaesthetists of Great Britain and Ireland.

Authors:  Nicholas Eustace; Brendan O'Hare
Journal:  Paediatr Anaesth       Date:  2007-05       Impact factor: 2.556

6.  Use of over-the-counter medicines for young children in Australia.

Authors:  Misel Trajanovska; Elizabeth Manias; Noel Cranswick; Linda Johnston
Journal:  J Paediatr Child Health       Date:  2009-11-23       Impact factor: 1.954

7.  Analysis of analgesic, antipyretic, and nonsteroidal anti-inflammatory drug use in pediatric prescriptions.

Authors:  Tânia R Ferreira; Luciane C Lopes
Journal:  J Pediatr (Rio J)       Date:  2015-10-09       Impact factor: 2.197

8.  Trends in Outpatient Prescription Medicine Use in New Zealand Children 2010-2015: A National Population-Based Study.

Authors:  Andrew M Tomlin; David J Woods; Hywel S Lloyd; Murray W Tilyard
Journal:  Paediatr Drugs       Date:  2018-10       Impact factor: 3.022

Review 9.  Nonsteroidal anti-inflammatory drugs for postoperative pain: a focus on children.

Authors:  Hannu Kokki
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Population-based analysis of non-steroidal anti-inflammatory drug use among children in four European countries in the SOS project: what size of data platforms and which study designs do we need to assess safety issues?

Authors:  Vera E Valkhoff; René Schade; Geert W 't Jong; Silvana Romio; Martijn J Schuemie; Andrea Arfe; Edeltraut Garbe; Ron Herings; Silvia Lucchi; Gino Picelli; Tania Schink; Huub Straatman; Marco Villa; Ernst J Kuipers; Miriam C J M Sturkenboom
Journal:  BMC Pediatr       Date:  2013-11-19       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.